Skip to main content

TA-8995-AD-1 New Amsterdam Pharma


TA-8995-AD-1 New Amsterdam Pharma

Leeftijd icoon
50-75 years
Diagnose icoon
Early stage of Alzheimer’s
Duratie onderzoek
36 weeks
Locatie icoon

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

The goal of this research is to find out how safe and potentially effective the new drug obicetrapib is for the treatment of participants with early-stage Alzheimer’s disease (mild cognitive impairment or beginning dementia). The research drug is taken in the form of a tablet.  

In Alzheimer’s disease, the different types of cholesterol are not present at the right levels. The study drug obicetrapib lowers levels of one kind of cholesterol (LDL cholesterol) and increases the level of another kind (HDL cholesterol). Also, in Alzheimer’s disease, the transport of cholesterol between cells in the brain works less well. Obicetrapib could potentially influence this process. It is possible that if these processes are addressed, the level of disease-causing proteins in the brain could decrease. Whether that actually happens, is the subject of this study. 

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 8 times, during approximately 36 weeks. In addition, you will also have several telephone conversations. The duration of a visit is not always the same because not every visit has the same checks. Some of these visits may last 6 hours, others 3.5 hours. A phone call takes around 15 minutes. 

This research is sponsored by NewAmsterdam Pharma. 

How does the application process go?

You always decide whether you participate in a study. Participation is always voluntary.

  1. You apply via the online form, this is non-binding.
  2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
  3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
  4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
  5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

What are the benefits of Brain Research Center?

  1. You always come first – everything we do revolves around you.
  2. Experienced team of doctors, neuropsychologists, and nurses.
  3. Open and homely atmosphere – this will make you feel relaxed and right at home.
  4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
  5. Always nearby – 3 locations spread through the Netherlands.

What's in it for me?

  • You may experience benefits from a new treatment.
  • You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
  • You make a meaningful contribution to a future without Alzheimer’s.
  • You contribute to the advancement of science.

Can I participate?

You can participate when:

  • You have the diagnosis of early-stage dementia due to Alzheimer’s disease.
  • You are between 50 and 75 years old.
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate. 

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials